Phaseline

Companies › MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apomorphine
D2-like dopamine receptor agonist
DRD2, DRD3, DRD4Phase 3Idiopathic Parkinson's Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02339064ApomorphinePhase 3Idiopathic Parkinson's DiseaseNeurologyDec 2018

Targets

DRD2 (1) DRD3 (1) DRD4 (1)

Companies with the same targets

Serina Therapeutics Boryung Pharmaceutical LB Pharmaceuticals Gedeon Richter Anxo Pharmaceutical Mapi Pharma AbbVie Prilenia Changchun GeneScience Pharmaceutical Vanda Pharmaceuticals

Companies built like this

Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.